Top Markets
#1 Nesa Nesa +803.49%
#2 Cortex Cortex +68.67%
#3 Kinesis Silver Kinesis Silver +55.82%
#4 Merlin's Seal BTC Merlin's Seal BTC +45.67%
#5 QuantixAI QuantixAI +24.00%
#6 EXOD EXOD +22.78%
#7 Cash Cat Cash Cat +22.43%
#8 Alchemist AI Alchemist AI +17.55%
#9 Pons Pons +16.98%
#10 Instadapp Instadapp +16.15%
Coin of the day
Nesa Nesa
การตั้งค่า
ภาษา
ไทย
สกุลเงิน
USD
ธีม
Molecular Partners AG Molecular Partners AG

Molecular Partners AG

MOLN
อันดับในหุ้น #19149
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
ราคาหุ้น
$4.62
มูลค่าตลาด
$173.19M
การเปลี่ยนแปลง (1 วัน)
4.11%
การเปลี่ยนแปลง (1 ปี)
26.63%
ประเทศ
CH
ซื้อขาย Molecular Partners AG (MOLN)

หมวดหมู่

Healthcare
ประวัติราคาหุ้นของ Molecular Partners AG (MOLN)
ราคาปิดสูงสุด: $4.41 เมื่อ 2026-08-01

ราคาปิดต่ำสุด: $24.56 เมื่อ 2015-03-01
ประวัติราคาหุ้นของ Molecular Partners AG ตั้งแต่ 2015 ถึง 2026
ผลการดำเนินงานราคาหุ้นรายปี
ปี ประสิทธิภาพ
2026 (TTM) -1.93%
2025 -21.29%
2024 23.60%
2023 -35.40%
2022 -60.06%
2021 -31.00%
2020 39.82%
2019 -1.96%
2018 -30.67%
2017 30.64%
2016 -40.17%
2015 0.00%
ราคาหุ้นของบริษัทที่คล้ายกันหรือคู่แข่ง
บริษัท ราคาหุ้น การเปลี่ยนแปลง 1ปี% ประเทศ
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.85%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 44.02%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 541.49%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.62 -12.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $768.11 6.75%
CH